Zanamivir microneedle patch - TSRL
Alternative Names: Zanamivir - TSRLLatest Information Update: 28 Jan 2023
At a glance
- Originator TSRL
- Class Antivirals; Guanidines; Pyrans; Sialic acids
- Mechanism of Action Neuraminidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA (Transdermal, Patch)
- 01 Jun 2021 PharmaTher and TSRL collaborate to develop microneedle patch delivery technology for psychedelics and antivirals
- 01 Jun 2021 TSRL in-licenses microneedle patch technology from the Queen’s University of Belfast